CJC-1295 No DAC vs CJC-1295 DAC: Key Differences for GH Research

CJC-1295 is one of the most widely studied growth hormone-releasing hormone (GHRH) analogs in peptide research. However, the designation "CJC-1295" is frequently used to describe two structurally distinct compounds — CJC-1295 No DAC and CJC-1295 with DAC (Drug Affinity Complex). Understanding the difference between these two peptides is essential for designing accurate GH axis research protocols.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates pituitary somatotrophs to release growth hormone. The original CJC-1295 compound was engineered to improve upon native GHRH(1-29), which has a very short half-life of approximately 7 minutes in vivo due to rapid enzymatic degradation. Both DAC and No DAC variants address this limitation — but through fundamentally different mechanisms.

CJC-1295 No DAC: Pulsatile GH Release

CJC-1295 No DAC (also known as Mod GRF 1-29) is a modified form of GHRH(1-29) with four amino acid substitutions that improve enzymatic stability. It does not contain the Drug Affinity Complex and therefore does not bind to albumin. Key research characteristics:

• Half-life: Approximately 30 minutes — significantly longer than native GHRH but still short enough to produce discrete, pulsatile GH release
• GH release pattern: Mimics the natural pulsatile secretion of GH, which is considered more physiological in research models
• Research use: Preferred when researchers want to study acute GH pulses or combine with a GH secretagogue such as Ipamorelin for synergistic pulsatile release
• Dosing frequency: Requires more frequent administration to maintain GH stimulation in research protocols

CJC-1295 with DAC: Sustained GH Elevation

CJC-1295 with DAC incorporates a lysine-maleimide linker (the Drug Affinity Complex) that enables covalent binding to serum albumin after administration. This dramatically extends its half-life:

• Half-life: 6–8 days in research models due to albumin binding
• GH release pattern: Produces sustained, blunted GH elevation rather than discrete pulses — sometimes referred to as a "GH bleed" in research literature
• Research use: Suited for studies examining chronic GH axis stimulation, IGF-1 elevation over time, or long-term metabolic effects
• Dosing frequency: Can be administered once or twice weekly in research protocols

Key Differences at a Glance

• Albumin binding: No DAC — none; DAC — covalent albumin binding via maleimide linker
• Half-life: No DAC ~30 min; DAC ~6–8 days
• GH pattern: No DAC — pulsatile; DAC — sustained elevation
• Combination use: No DAC pairs well with Ipamorelin or other GHS peptides; DAC is typically used as a standalone GHRH analog
• Physiological relevance: No DAC more closely mimics endogenous GHRH signaling patterns

CJC-1295 No DAC + Ipamorelin: The Standard Research Combination

The most frequently studied GH research combination pairs CJC-1295 No DAC with Ipamorelin. CJC-1295 No DAC amplifies the GH pulse via GHRH receptor activation, while Ipamorelin triggers release via GHS-R1a agonism. Together they produce a synergistic, physiologically patterned GH pulse that is widely used in preclinical body composition, metabolic, and recovery research.

Which Variant to Use in Research?

The choice between No DAC and DAC depends on the research objective. For studies requiring pulsatile GH dynamics, acute pituitary responsiveness, or combination protocols with GH secretagogues, CJC-1295 No DAC is the appropriate tool compound. For studies examining sustained IGF-1 elevation, chronic GH axis stimulation, or long-interval dosing models, CJC-1295 with DAC may be more suitable. Researchers should select the variant that aligns with the specific GH release pattern relevant to their study design.

Summary

CJC-1295 No DAC and CJC-1295 with DAC are distinct research compounds with different pharmacokinetic profiles and GH release patterns. No DAC produces short, pulsatile GH release suitable for acute and combination research protocols, while DAC produces sustained GH elevation suited for chronic stimulation studies. Understanding this distinction is fundamental to designing reproducible GH axis research.

All content on this page is intended for research and educational purposes only. QuickPen Pro peptides are sold exclusively for laboratory and scientific research use.